Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of SOM Biotech.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
SOM Biotech
Spain_new Flag
Country
Country
Spain
Address
Address
Baldiri Reixac, 4 (08028) Barcelona
Telephone
Telephone
+34 934 020 150

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

This agreement follows the completion of research agreement, in which the University of Minnesota conducted a series of in vitro studies on potential pre-clinical product candidates for Duchenne and Becker muscular dystrophy identified using SOM Biotech’s platform, SOMAIPRO.


Lead Product(s): Undisclosed

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: University of Minnesota

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 17, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SOM3355 has potential to be an alternative to current VMAT2 inhibitors with a significantly improved side effect profile for the treatment of chorea in Huntington´s disease.


Lead Product(s): SOM3355

Therapeutic Area: Genetic Disease Product Name: SOM3355

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 18, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SOM3355, an oral vesicular monoamine transporter 2 (VMAT2) inhibitor for the symptomatic treatment of chorea movements associated with Huntington’s disease (HD).


Lead Product(s): SOM3355

Therapeutic Area: Genetic Disease Product Name: SOM3355

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 04, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

In vitro experiments confirmed inhibition of the protease with an IC50 in the low micromolar range. Eravacycline inhibits the infection of SARS-CoV-2 in VeroE6 cells and shows no toxicity when applied alone.


Lead Product(s): Eravacycline

Therapeutic Area: Infections and Infectious Diseases Product Name: TP-434

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 19, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY